(209 days)
Not Found
Not Found
No
The summary describes a standard blood glucose monitoring system and lacks any mention of AI, ML, image processing, or data analysis beyond quantitative determination of glucose levels.
Yes
The device is intended to assist in the management of diabetes, which is a therapeutic purpose.
Yes
This device, the TrueTrack Smart System Blood Glucose Test System, is intended for the "quantitative determination of glucose in human whole blood" and is used "to assist the patient and healthcare professional in the management of diabetes." This determination of a physiological state (glucose levels) for disease management clearly falls under the definition of a diagnostic device.
No
The description explicitly states "Blood Glucose Test System" and mentions taking blood samples, which strongly implies the use of hardware (a meter, test strips, lancet, etc.) to perform the glucose measurement. The lack of a "Device Description" section prevents a definitive confirmation, but the intended use points away from a software-only device.
Yes, based on the provided information, the TrueTrack Smart System Blood Glucose Test System is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "quantitative determination of glucose in human whole blood." This involves testing a biological sample (blood) outside of the body (in vitro) to diagnose or monitor a medical condition (diabetes).
- Nature of the Test: Measuring glucose levels in blood is a classic example of an in vitro diagnostic test.
The other sections, while relevant to a full device description, don't contradict or negate the IVD nature of the device as defined by its intended use.
N/A
Intended Use / Indications for Use
The TrueTrack Smart System Blood Glucose Test System is intended for the quantitative determination of glucose in human whole blood taken from the finger or forearm. The System is intended to be used to assist the patient and healthcare professional in the management of diabetes.
Product codes
CGA, NBW, JJX
Device Description
TrueTrack Smart System Blood Glucose Monitoring System
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
finger or forearm (human whole blood)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
patient and healthcare professional
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three stripes representing health, services, and people. The eagle is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA".
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAR 2 4 2004
Ms. Karen DeVincent Director, Regulatory Affairs/ Quality Assurance Home Diagnostics, Inc. 2400 NW. 55th Ct. Fort Lauderdale, FL 33309
Re: K032657
Trade/Device Name: TrueTrack Smart System Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Code: CGA, NBW, JJX Dated: March 3, 2004 Received: March 5, 2004
Dear Ms. DeVincent:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
1
Page 2
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Jean M. Cooper, MS, DVM.
Yean M. Cooper, MS, D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
2
of ___________________________________________________________________________________________________________________________________________________________________________ Page -
510(k) Number (if known): K032657
Device Name: TrueTrack Smart System Blood Glucose Monitoring System
Indications For Use:
The TrueTrack Smart System Blood Glucose Test System is intended for the quantitative determination of glucose in human whole blood taken from the finger or forearm. The System is intended to be used to assist the patient and healthcare professional in the management of diabetes.
Alberto Zerts
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K032657
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Oer 21 CFR 801.109)
OR
Over-The-Counter Use V
(Optional Format 1-2-96)